Belgium —- On October 6, 2014, Biogazelle announced the closure of an

investment round with QBIC Arkiv Fund, Foundation Majoie and SOFI to finance its growth

(press release available on https://bgzlle.com/1sVQfEJ). Today, Biogazelle announces that it

has strengthened its board with two directors representing the new investors and also

announces its intention to propose the nomination of Nick McCooke and Jim Van heusden

as non-executive directors to the next shareholder meeting. Biogazelle’s board also has the

intention to separate the roles of chairman and CEO. The board intends to elect Nick

McCooke as chairman to succeed Jan Hellemans who will remain chief executive officer.

The new members will join the current board members (Jan Hellemans (CEO), Jo

Vandesompele (CSO), Bert D’Huyvetter (CFO) and Marc Schijvaerts) who retain their

appointment.

Nick McCooke, independent chairman

Nick is an experienced and successful bio-entrepreneur, well-known for building

and leading the Solexa team that pioneered Next Generation Sequencing

(NGS), technology that became the basis of Illumina’s current market-leading

product line. Apart from his base in the UK, Nick has lived and worked in the

USA, Japan and Belgium. He acted as CEO of Pronota, interim COO of

Cambridge Epigenetix, part-time CEO of Oxford Cancer Biomarkers and CEO

of Solexa. Nick is currently CBO of DNA Electronics, a non-executive director of

Bioventix PLC and a trustee of the Association of Medical Research Charities.

Bernard Majoie, representing Foundation Majoie

Bernard Majoie is founder of the research & development laboratory of the

Fournier Group. He acted as CSO, CEO and finally Chairman of the board at

Fournier Pharmaceutical Group. When retiring he played a Business Angel

activity helping start-ups in Belgium and France. He is currently chairman and

founder of the Fournier-Majoie Foundation dedicated to support innovative

and entrepreneurial teams in biomolecular applications leading to

improvements of cancer treatments.

Els Hubloux, representing QBIC Arkiv Fund

Els is an Investment Partner at QBIC Venture Partners. She has over 18 years of

experience in the life sciences sector, of which 12 years as a venture capital

professional. She has also acted as CFO of a diagnostics start-up and has been

a director of a number of companies, including Algonomics, Nexstim, Sequana

Medical, Sphere Medical and TcLand Expression.

Jim Van heusden, independent board member appointed by SOFI

Jim Van heusden is Managing Director of bioskills, providing fundraising services

and strategic advice to biotech companies and life science funds. He has

over 20 years of experience in the life sciences sector, of which 12 years as a

venture capital investor in biotech companies at Gimv.